A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries.
A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries. Subjects of prospective study will be randomly divided using electronic program into two groups: The first group will receive intraoperative local Liposomal Bupivacaine injection at the port placement site. The control group will receive will local Marcaine (bupivacaine HCl) injection Primary Outcome Measures: * Total opioid consumption measured in intravenous morphine equivalents dose during the postoperative hospital Stay * Postoperative pain assessment using visual Analog Pain Scores \& Brief Pain Inventory form. * Length of Hospital Stay * Time to First Opioid Use. * Postoperative Constipation , paralytic ileus
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
136
Loma Linda Medical Center
Loma Linda, California, United States
Total Opioid Consumption
Postoperative analgesic use will be measured in oral morphine equivalents dose given to patients in the first three days postoperatively
Time frame: Postoperative days 1-3
Postoperative Pain Assessment
Pain score (0-10) will be used. This will be based on a standard visual analog scale, where 0 indicates no pain and 10 indicates the most severe pain reported by patients.
Time frame: Postoperative day 1
Length of Hospital Stay
Duration of hospital stay after the surgery until time of discharge
Time frame: Duration of stay in hours
Postoperative Complications
Any complication related to the surgery within 30 days
Time frame: 30 days postoperatively
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.